Sunitinib-Induced Acute Liver Failure
| Autor: | Sami Droubi, Anum Aqsa, Shivantha Amarnath, Hassan Almoussawi, Jeffrey Abergel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Stromal cell Side effect medicine.drug_class Cardiomyopathy urologic and male genital diseases Gastroenterology Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine Case and Review Internal medicine medicine Sunitinib lcsh:RC799-869 Liver injury Tyrosine kinase inhibitors business.industry Incidence (epidemiology) Liver failure medicine.disease female genital diseases and pregnancy complications 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology lcsh:Diseases of the digestive system. Gastroenterology business Acute liver failure medicine.drug |
| Zdroj: | Case Reports in Gastroenterology Case Reports in Gastroenterology, Vol 15, Iss 1, Pp 17-21 (2021) |
| ISSN: | 1662-0631 |
| Popis: | Drug-induced liver injury is an uncommon but life-threatening entity. Sunitinib is a tyrosine kinase inhibitor used for advanced and imatinib-refractory gastrointestinal stromal tumors. It causes transient elevation in liver enzymes. The incidence of fatal acute liver failure is rare. Five cases of sunitinib-induced acute liver injury have been reported in the literature thus far. We present a case of fatal acute liver failure and cardiomyopathy within 2 weeks of sunitinib therapy initiation for advanced pancreatic neuroendocrine carcinoma. We believe our case is unique due to the rarity of its presentation. It highlights hepatotoxicity as a potentially fatal side effect of sunitinib therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|